AMED SCARDA「ワクチン開発のための世界トップレベル研究開発拠点の形成事業」合同シンポジウム

*Yoshiyuki Goto^1,2,3, Bonita Lynn McCuaig¹ (1. Medical Mycology Research Center, Chiba University (Japan), 2. Research Institute of Disaster Medicine, Chiba University (Japan), 3. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba Universi-ty (Japan))

*Takashi Ito

*Emiko Urano¹, Yasuhiro Yasutomi¹ (1. Tsukuba Primate Research Center, NIBIOHN (Japan))

*石垣 宏仁¹
*Hitohito Ishigaki¹, Hiraku Kokubu^1,2, Kenichi Otaki¹, Yasushi Itoh¹ (1. Dept of Pathology, Pathogenesis and Disease Regulation, Shiga University of Medical Science (Japan), 2. Dept of Dermatology, Shiga University of Medical Science (Japan))

David Priest², Takeshi Ebihara⁴, Janyerkye Tulyea¹, Jonas Sondergaard¹, Hisatake Matsumoto⁴, *James Wing^1,2,3 (1. CiDER, Osaka University (Japan), 2. IFReC, Osaka University (Japan), 3. CAMaD, Osaka University (Japan), 4. Graduate School of Medicine, Osaka University (Japan))

*Yukinori Okada^1,2,3, Akari Suzuki¹, Kazuhiko Yamamoto¹ (1. RIKEN Center for Integrative Medical Sciences (Japan), 2. The University of Tokyo (Japan), 3. Osaka University (Japan))

*Kaidre Bendjama^1,2, Ioannis Vardaxis², Alexandru Odainic², Sebastian Kapell², Akhilesh Sharma³ (1. University of Nagasaki (Japan), 2. NEC Oncoimmunity (Norway), 3. NEC Corporation (Japan))

*Yoshimasa Tanaka¹, Makoto Matsumoto¹, Longjian Geng¹, Mariko Kamiya¹, Kazuya Okami¹, Shigeru Kawakami¹ (1. Nagasaki University (Japan))

*Yuki Furuse¹, Ryo Komorizono¹, Naoko Fujita¹ (1. UTOPIA, University of Tokyo (Japan))